From Target to Clinic: Development & Manufacturing of the First in Class VARTUMAB ADC
10:45 am - Tuesday 9th March 2027
- Oncofetal chondroitin sulfate, an abundant pan-cancer target present on cancer cells and in the tumour stroma
- Selecting a monovalent scFv–Fc VARTUMAB ADC format, enabling a homogeneous DAR2 construct with deep tumour penetration and potent bystander activity
- Highlighting GMP manufacturing and control of VARTUMAB ADC achieving high yield, purity and stability
